The famous American virologist – HIV virus discoverer Robert Gallo joined Medisun Medical Groupedisun Bringing the best cancer and AIDS treatment technologies to China Robert Gallo, a famous American virologist, joined Medisun Medical Groupedisun In February 2017, Medisun Medical Group officially announced the appointment of Robert Charles Gallo, a famous American virologist, as a member of the board of directors of the group.   Dr. Robert Charles Gallo Dr. Gallo is a famous American virologist whose best-known contribution is the discovery of the first human retrovirus (HTLV1, and HTLV2). In 1983, HTLV3 was discovered, which was later called the HIV, …

Hong Kong National Investment and Harvard University Stem Cell Institute have a strong cooperation. Mr. Brock Reeve, CEO of Harvard Stem Cell Research Institute, is the Chief Investment Officer of Stem Cell and Regenerative Medisun at National Investment and Medici Medical Group. 2015-05-11 China Securities Journal On May 8, 2015, Hong Kong Medisun Regerative Medical Center and National Investment (01227.HK) announced the appointment of Mr. Brock Reeve as the chief stem cell and regenerative medicine investment officer of the two companies. Mr. Brock Reeve is currently the Executive Director of the Harvard University Stem Cell Institute and has graduated from …

Medisun Medical Group 2015-01-26, Taking the first year of China’s medical reform in 2015 as an opportunity, Mayo and Medisun have joined forces to enter the Chinese medical market in large numbers. It can be said that it is at the right time. Dr. Cao Shengyu, President of Medici Medical Group, former General Manager of Hong Kong Queen Elizabeth Hospital and General Manager of Kowloon China Network and managing the five public hospitals, said: “Based on our experience in investing in hospitals in Hong Kong and China over the past 20 years, and in the new environment of China’s medical …

Cardio3 BioSciences teams up with Medisun International to create Cardio3 BioSciences Asia Holdings Ltd, a Joint Venture aimed at conducting pivotal clinical programs in Greater China • The minimum of 20M€ funding of the Joint Venture over the next three years is secured by local financial investors led by Hong Kong based Medisun International Ltd. • The clinical program aims to lead to the commercialization of C-Cure® in the People’s Republic of China, Hong Kong and Taiwan. • Medisun will also bring local regulatory, clinical and market access knowledge, while Cardio3 BioSciences will bring clinical and operational knowhow and expertise. …